Orilanolimab  (Synonyms: SYNT001)

Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity^[1][2].

Interaction between FcRn and IgG^[1]

Orilanolimab (10 nM, 50 nM, and 100 nM; 48 h) inhibits interferon IFN-γ production in CD11c⁺ Ag-presenting cells (APCs) from B2M^TG/TGFCGRT^TG/TGFcgrt^-/- mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Orilanolimab (20 mg/kg; i.v.) significantly reduces the plasma concentration of HuLys11 in mouse model^[1].
Orilanolimab (10-100 mg/kg; i.v.; once per 5 weeks) causes dose-dependent and specific reduction of total circulating levels of IgG cynomolgus monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2066544-85-0

Liquid

Colorless to light yellow

[Orilanolimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019 Dec 18;5(12):eaax9586.  [Content Brief]

  [2]. Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. Blood, 2017, 130: 3483.